exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • Esbriet

    • Drug: Esbriet (pirfenidone)
    • Manufacturer: Genentech

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of idiopathic pulmonary fibrosis
    • Disease: idiopathic pulmonary fibrosis (IPF)

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: Prescription Form
    • Phone Number: 888-941-3331
    • Fax Number: 833-999-4363
    • Product Website: esbriet.com

  • Gimoti

    • Drug: Gimoti (metoclopramide)
    • Manufacturer: Evoke Pharma
    • Route of Administration: Intranasal

    • Site of Care: Outpatient

    • Approved Indication: relief of symptoms in adults with acute and recurrent diabetic gastroparesis

    • Disease: gastroparesis

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: www.gimotirx.com/forms

    • Phone Number: 1-844-2GIMOTI (1-844-244-6684)
    • Fax Number: 1-888-661-9657
    • Product Website: gimotirx.com

  • Hadlima

    • Drug: Hadlima (adalimumab-bwwd)
    • Manufacturer: Organon

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
        • treatment of moderately to severely active ulcerative colitis in adult patients
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in adult patients
        • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
    • Enrollment Form Link: www.hadlima.com/co-pay-assistance-enrollment
    • Phone Number: 1-855-460-7928
    • Fax Number: 1-888-777-5645
    • Product Website: hadlima.com

  • Harvoni

    • Drug: Harvoni (ledipasvir/sofosbuvir)
    • Manufacturer: Gilead

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of chronic hepatitis C virus in adults and pediatric patients 3 years of age and older with either

      • genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis
      • genotype 1 with decompensated cirrhosis in combination with ribavirin
      • genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis in combination with ribavirin

    • Disease: chronic viral hepatitis C

    • Therapeutic Area: Infectious disease, Gastroenterology, Hepatology
    • Enrollment Form Link: mysupportpath.com/liver
    • Phone Number: 1-855-7-MYPATH (1-855-769-7284)

    • Fax Number: 1-855-298-8700

    • Product Website: harvoni.com

  • Hulio

    • Drug: Hulio (adalimumab-fkjp)
    • Manufacturer: Organon

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
        • treatment of moderately to severely active ulcerative colitis in adult patients
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in adult patients
        • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: hulio.fvfn.net/#/

    • Phone Number: 1-855-460-7928

    • Fax Number: 1-888-777-5645
    • Product Website: hulio.com

  • Humira

    • Drug: Humira (adalimumab)
    • Manufacturer: AbbVie

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
        • treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older
        • treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older

    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.abbvie.com/patients/patient-support

    • Phone Number: 1-800-488-6472
    • Fax Number: 1-800-783-7050
    • Product Website: humira.com

  • Hyrimoz

    • Drug: Hyrimoz (adalimumab-adaz)
    • Manufacturer: Sandoz

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
        • treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older
        • treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older

    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.hyrimoz.com/support

    • Phone Number: 1-833-HYRIMOZ (1-833-497-4669)

    • Fax Number: 1-844-600-0449
    • Product Website: hyrimoz.com

  • Ibsrela

    • Drug: Ibsrela (tenapanor)
    • Manufacturer: Ardelyx

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of irritable bowel syndrome with constipation in adults

    • Disease: irritable bowel syndrome with constipation (IBS-C)
    • Therapeutic Area: Gastroenterology
    • Enrollment Form Link: ibsrela-hcp.com/prescribing
    • Phone Number: 844-427-7352
    • Fax Number: 877-765-7664
    • Product Website: ibsrela.com

  • Idacio

    • Drug: Idacio (adalimumab-aacf)
    • Manufacturer: Fresenius Kabi

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adult patients
        • treatment of moderately to severely active ulcerative colitis in adult patients
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in adult patients
        • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.kabicare.us/IDACIO-Patient-Enrollment-and-Prescription-Form

    • Phone Number: 1-833-KABICARE (1-833-522-4227)
    • Fax Number: 1-833-671-1010
    • Product Website: kabicare.us/idacio

  • Imuldosa

    • Drug: Imuldosa (ustekinumab-srlf)
    • Manufacturer: Accord BioPharma

    • Route of Administration: Intravenous, Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

      • treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
      • treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older
      • treatment of moderately-to-severely active Crohn’s disease in adults
      • treatment of moderately-to-severely active ulcerative colitis in adults

    • Disease: Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: N/A

    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: N/A